UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month
of August 2024
Commission File
No. 001-38691
AURORA
CANNABIS INC.
(Translation of registrant's name into English)
2207 90B St. SW
Edmonton, Alberta T6X 1V8
Canada
(Address of principal executive office)
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☐
Form 40-F ☒
SUBMITTED HEREWITH
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AURORA CANNABIS INC.
/s/ Miguel Martin
Miguel Martin
Chief Executive Officer
Date: August 7, 2024
Exhibit 99.1
Aurora Cannabis Announces Fiscal 2025 First Quarter
Results and Delivers Positive Free Cash Flow
- Delivers Positive Free Cash Flow1 of $6.5 Million
- Increases Total Quarterly Net Revenue1 by 12%
YoY to $83.4 Million, Record Net Revenue1 of $47.2 Million in Global Medical Cannabis
- Generates Adjusted EBITDA1 of $4.9 Million, a
YoY increase of 87%
- Ends the Fiscal Quarter with a Debt-Free Cannabis Business2
and a Cash Position of ~$182 Million
EDMONTON, AB, Aug. 7, 2024 /CNW/ - Aurora Cannabis
Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis
company, today announced its financial and operational results for the first quarter fiscal 2025.
"This was a milestone quarter for Aurora, as
we delivered strong net revenue1 growth, a substantial increase in adjusted EBITDA1, and positive free cash flow1.
Our impressive performance was driven by record net revenue1 in the rapidly growing global medical cannabis segment, and we
look forward to building on our achievements in key markets such as Germany, Australia, and the UK throughout fiscal 2025 and beyond.
The quarter was further supported by a record contribution from our Bevo plant propagation business, underscoring the strength of our
diversified business model," said Chief Executive Officer Miguel Martin.
"The progress we made during the quarter sets
a strong foundation for the rest of the fiscal year, and with our continued commitment to operational excellence and strategic growth,
we are well-positioned to sustain this positive momentum. Our growth in global medical, the highest margin cannabis segment, alongside
our strong balance sheet and ongoing fiscal discipline, are pivotal as we build on our achievement with respect to positive free cash
flow," Mr. Martin concluded.
| |
| 1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures. |
| 2 Aurora's only remaining debt is non-recourse debt of $52.4 million relating to Bevo Farms Ltd as detailed in the FY2025 Q1 Financial Statements |
First Quarter 2025 Highlights
(Unless otherwise stated, comparisons are made
between fiscal Q1 2025, Q4 2024, and Q1 2024 results and are in Canadian dollars)
Consolidated Revenue and Adjusted Gross Profit:
Total net revenue1 was $83.4 million, as compared to $74.7 million in the prior year period. The 12% increase from
the prior period was mainly due to 13% growth in our global medical cannabis business and 16% growth in our plant propagation business,
slightly offset by lower quarterly revenue in our consumer cannabis.
Consolidated adjusted gross margin before fair value
adjustments1 was 43% in Q1 2025 and 44% in the prior year quarter. Adjusted gross profit before FV adjustments1 was $36.0 million
in Q1 2025 vs $32.6 million in the prior year quarter, an increase of 10%.
Medical Cannabis:
Medical cannabis net revenue1 was $47.2 million, a 13% increase from the prior year quarter, delivering 57% of Aurora's
Q1 2025 consolidated net revenue1 and 91% of adjusted gross profit before fair value adjustments1.
The increase in net revenue1 of $5.6 million was primarily
due to higher sales to Australia and a steady increase in sales in Canada to insurance covered patients and larger basket sizes.
Adjusted gross margin before fair value adjustments1
on medical cannabis net revenue reached 69% for the three months ended June 30, 2024, compared to 61% in the prior year quarter. Our target
range is 60% and above. The adjusted gross margins before fair value adjustments improved through sustainable cost reductions, higher
selling prices in Australia, and improved efficiency in production operations, including sourcing for Europe from Canada due to the closure
of the Aurora Nordic production facility.
Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was $11.5 million, a 10% decrease compared to $12.8 million in the prior year
quarter. The decrease was due to our decision to prioritize the supply of our GMP manufactured products to our high margin international
business rather than the consumer business, which offers lower margins.
Adjusted gross margin before fair value adjustments1
on consumer cannabis net revenue1 was 24%, decreasing from 26% compared to the prior year quarter. The decrease from the prior
year comparative quarter is largely due to higher margin product sales.
Plant Propagation:
Plant propagation net revenue1 was wholly comprised of the Bevo business, and contributed $23.1 million of net revenue1,
a 16% increase compared to $19.9 million in the prior year quarter. The increase was a result of organic growth and increased product
offerings. Historically, approximately 65-75% of plant propagation revenue and up to 80% of EBITDA has been earned in the first half of
the calendar year.
Adjusted gross margin before fair value adjustments1
on plant propagation revenue was 18% for Q1 2025 and 22% for the prior year quarter. The fluctuations in the plant propagation adjusted
gross margin before fair value adjustments is due to changes in product mix and a prolonged Spring season in the current quarter.
Selling, General and Administrative ("SG&A"):
Adjusted SG&A1 was $31.4 million in Q1 2025, which excludes $4.9 million of business transformation costs. Adjusted
SG&A1 is likely to remain above our previous target of $30 million due to the incremental SG&A following the acquisition
of MedReleaf Australia.
Adjusted R&D1, was $1.0 million in
Q1 2025, which is relatively consistent as compared to the prior year quarter at $1.1 million. Our investment in R&D and product innovation
is partly opportunistic, as such these costs will vary quarter over quarter and year over year.
Net Income (Loss):
Net income from continuing operations for the three months ended June 30, 2024 was $4.8 million compared to net loss of $20.2
million for the prior year period.
Adjusted EBITDA:
Adjusted EBITDA1 increased 87%to $4.9 million for the three months ended June 30, 2024 compared to $2.6 million for
the prior year quarter.
Fiscal Q2 2025 Expectations:
We expect to see continued strong net revenue and adjusted gross margins across our cannabis business, supported by net revenue1
growth in Europe and Australia.
For plant propagation, we expect to see seasonally
reduced revenues and gross profit in Q2 2025 that will be in line with historical performance as 25% – 35% of revenues are normally
earned in the second half of a calendar year.
Positive adjusted EBITDA is expected to continue while
free cash flow is anticipated to be negatively impacted by several significant annual and one-time cash payments that typically occur
in Q2 2025.
Key Quarterly Financial Results
| |
Three months ended |
| ($ thousands, except Operational Results) |
June 30,
2024 |
March 31,
2024(4) |
$ Change |
% Change |
June 30,
2023(4) |
$ Change |
% Change |
| Financial Results |
|
|
|
|
|
|
|
| Net revenue (1)(2a) |
$83,435 |
$67,411 |
$16,024 |
24 % |
$74,732 |
$8,703 |
12 % |
| Medical cannabis net revenue (1)(2a) |
$47,201 |
$45,648 |
$1,553 |
3 % |
$41,615 |
$5,586 |
13 % |
| Consumer cannabis net revenue (1)(2a) |
$11,533 |
$10,233 |
$1,300 |
13 % |
$12,842 |
($1,309) |
(10 %) |
| Plant propagation revenue |
$23,081 |
$10,416 |
$12,665 |
122 % |
$19,904 |
$3,177 |
16 % |
| Adjusted gross margin before FV adjustments on total net |
|
|
|
|
|
|
|
| revenue (2b) |
43 % |
50 % |
N/A |
(7 %) |
44 % |
N/A |
(1 %) |
| Adjusted gross margin before FV adjustments on cannabis |
|
|
|
|
|
|
|
| net revenue (2b) |
53 % |
54 % |
N/A |
(1 %) |
52 % |
N/A |
1 % |
| Adjusted gross margin before FV adjustments on medical |
|
|
|
|
|
|
|
| cannabis net revenue (2b) |
69 % |
66 % |
N/A |
3 % |
61 % |
N/A |
8 % |
| Adjusted gross margin before FV adjustments on |
|
|
|
|
|
|
|
| consumer cannabis net revenue (2b) |
24 % |
16 % |
N/A |
8 % |
26 % |
N/A |
(2 %) |
| Adjusted gross margin before FV adjustments on plant propagation net revenue (2b) |
18 % |
25 % |
N/A |
(7 %) |
22 % |
N/A |
(4 %) |
| Adjusted SG&A expense(2d) |
$31,396 |
$31,351 |
$45 |
0 % |
$29,033 |
$2,363 |
8 % |
| Adjusted EBITDA (2c) |
$4,887 |
$2,319 |
$2,568 |
111 % |
$2,619 |
$2,268 |
87 % |
| Free cash flow (2e) |
$6,490 |
($21,866) |
$28,356 |
(130 %) |
($11,686) |
$18,176 |
(156 %) |
| Balance Sheet |
|
|
|
|
|
|
|
| Working capital (2f) |
$322,563 |
$301,985 |
$20,578 |
7 % |
$192,201 |
$130,362 |
68 % |
| Cannabis inventory and biological assets (3) |
$173,197 |
$148,112 |
($62,672) |
(42 %) |
$100,846 |
($15,406) |
(15) % |
| Total assets |
$838,689 |
$838,673 |
$16 |
0 % |
$832,188 |
$6,501 |
1 % |
| (1) |
Includes the impact of actual and expected product returns and price adjustments (Q1 2025 – nil; Q1 2024 - $0.6 million Q4 2024 – nil). |
| (2) |
These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure: |
| |
a. |
Refer to the "Revenue" and "Cost of Sales and Gross Margin" section for a reconciliation of cannabis net revenue to the IFRS equivalent. |
| |
b. |
Refer to the "Adjusted Gross Margin" section for reconciliation to the IFRS equivalent. |
| |
c. |
Refer to the "Adjusted EBITDA" section for reconciliation to the IFRS equivalent. |
| |
d. |
Refer to the "Operating Expenses" section for reconciliation to the IFRS equivalent. |
| |
e. |
Refer to the "Liquidity and Capital Resources" section for a reconciliation to the IFRS equivalent. |
| |
f. |
"Working capital" is defined as Current Assets less Current Liabilities as reported on the Company's Consolidated Statements of Financial Position. |
| (3) |
Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets. |
| (4) |
Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Conference Call
Aurora will host a conference
call today, Wednesday, August 7, 2024, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief
Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session
will follow management's presentation.
| DATE: |
Wednesday, August 7, 2024 |
| TIME: |
8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time |
| WEBCAST: |
Click Here |
This weblink has also been posted
to the Company's "Investor Info" link at https://www.auroramj.com/investors/ under "Events".
About Aurora Cannabis
Aurora is opening the world to
cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton,
Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio
includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora
and Whistler Medical Marijuana Co., as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling
interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and
with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness
and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade
on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Statements
This news release includes statements
containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's Q1 FY2025
results, statements under the heading "Fiscal Q2 2025 Expectations", including as related to net cannabis revenue growth
and adjusted gross margins, revenue and gross profit in the plant propagation segment, and expectations for positive adjusted EBITDA and
free cash flow, statements regarding the Company's continued commitment to operational excellence and strategic growth, sustained positive
momentum, and expectations for SG&A and R&D expenses, as well as those statements regarding the Company's conference call to discuss
results.
These forward-looking statements
are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions
management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without
limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions
based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a
variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause
actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected
in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue
investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products,
customer experience and retention, the development of third party government and nongovernment consumer sales channels, management's estimates
of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of
successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue
growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market
conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the
possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, and other
risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated June
20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedarplus.com
and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other
factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider
the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance
on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable
securities law.
The Company's AIF, MD&A and annual financial statements,
which have been filed on SEDAR+ and with the SEC, are also available on the Company's website www.auroramj.com and shareholders may receive
hard copies free of charge upon request by contacting aurora@icrinc.com.
Non-GAAP Measures
This news release contains reference
to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result,
this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should
be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results,
underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to
provide additional information and to assist management and investors in assessing financial performance and should not be considered
in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading
"Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis
for the fiscal period ended June 30, 2024 (the "MD&A") is incorporated by reference into this news release. The MD&A
is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the SEC's EDGAR website at www.sec.gov.
Net Revenue, Adjusted Gross
Profit and Margin
Net revenue, adjusted gross profit
before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross
profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:
| ($ thousands) |
Medical
Cannabis |
Consumer
Cannabis |
Wholesale
Bulk Cannabis |
Total
Cannabis |
Plant
Propagation |
Total |
| Three months ended June 30, 2024 |
|
|
|
|
|
|
| Gross revenue |
50,121 |
17,215 |
1,620 |
68,956 |
23,081 |
92,037 |
| Excise taxes |
(2,920) |
(5,682) |
— |
(8,602) |
— |
(8,602) |
| Net revenue (1) |
47,201 |
11,533 |
1,620 |
60,354 |
23,081 |
83,435 |
| Non-recurring net revenue adjustments (2)(4)(5) |
— |
— |
— |
— |
(369) |
(369) |
| Adjusted net revenue |
47,201 |
11,533 |
1,620 |
60,354 |
22,712 |
83,066 |
| Cost of sales |
(16,902) |
(10,557) |
(6,212) |
(33,671) |
(19,639) |
(53,310) |
| Depreciation |
1,705 |
1,041 |
612 |
3,358 |
1,022 |
4,380 |
| Inventory impairment and non-recurring costs included in |
|
|
|
|
|
|
| cost of sales (2)(5) |
800 |
733 |
431 |
1,964 |
(118) |
1,846 |
| Adjusted gross profit (loss) before FV adjustments (1) |
32,804 |
2,750 |
(3,549) |
32,005 |
3,977 |
35,982 |
| Adjusted gross margin before FV adjustments (1) |
69 % |
24 % |
(219 %) |
53 % |
18 % |
43 % |
| Three months ended March 31, 2024(7) |
|
|
|
|
|
|
| Gross revenue |
48,466 |
15,240 |
1,114 |
64,820 |
10,416 |
75,236 |
| Excise taxes |
(2,818) |
(5,007) |
— |
(7,825) |
— |
(7,825) |
| Net revenue(1) |
45,648 |
10,233 |
1,114 |
56,995 |
10,416 |
67,411 |
| Non-recurring revenue adjustments (4,5) |
— |
— |
— |
— |
$ (192) |
(192) |
| Adjusted net revenue |
45,648 |
10,233 |
1,114 |
56,995 |
10,224 |
67,219 |
| Cost of sales |
(20,795) |
(11,682) |
(2,686) |
(35,163) |
(8,327) |
(43,490) |
| Depreciation |
2,262 |
1,195 |
284 |
3,741 |
660 |
4,401 |
| Inventory impairment, non-recurring, out-of-period, and |
|
|
|
|
|
|
| market development costs included in cost of sales (2)(3)(4)(5)(6) |
2,985 |
1,842 |
438 |
5,265 |
42 |
5,307 |
| Adjusted gross profit (loss) before FV adjustments (1) |
30,100 |
1,588 |
(850) |
30,838 |
2,599 |
33,437 |
| Adjusted gross margin before FV adjustments (1) |
66 % |
16 % |
(76 %) |
54 % |
25 % |
50 % |
| Three months ended June 30, 2023(7) |
|
|
|
|
|
|
| Gross revenue |
43,872 |
17,051 |
371 |
61,294 |
19,904 |
81,198 |
| Excise taxes |
(2,257) |
(4,209) |
— |
(6,466) |
— |
(6,466) |
| Net revenue(1) |
41,615 |
12,842 |
371 |
54,828 |
19,904 |
74,732 |
| Non-recurring net revenue adjustments (4) |
(598) |
(249) |
— |
(847) |
— |
(847) |
| Adjusted net revenue |
41,017 |
12,593 |
371 |
53,981 |
19,904 |
73,885 |
| Cost of sales |
(24,390) |
(15,970) |
(822) |
(41,182) |
(18,951) |
(60,133) |
| Depreciation |
2,776 |
1,643 |
85 |
4,504 |
870 |
5,374 |
| Inventory impairment, and non-recurring adjustments |
|
|
|
|
|
|
| included in cost of sales (2)(4)(5) |
5,692 |
5,010 |
242 |
10,944 |
2,501 |
13,445 |
| Adjusted gross profit (loss) before FV adjustments (1) |
25,095 |
3,276 |
(124) |
28,247 |
4,324 |
32,571 |
| Adjusted gross margin before FV adjustments (1) |
61 % |
26 % |
(33 %) |
52 % |
22 % |
44 % |
| (1) |
These terms are Non-GAAP Measures and are note recognized, defined or standardized measures under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
| (2) |
Inventory impairment includes inventory write-downs due to lower of cost or net realizable value adjustments, obsolescence provision adjustments, and inventory destruction. |
| (3) |
Markets under development represents the adjustment for business operations focused on developing international markets prior to commercialization. |
| (4) |
Non-recurring items includes inventory count adjustments resulting from facility shutdowns and abnormal fluctuations in utilities costs in the plant propagation business. |
| (5) |
Non-recurring items includes business transformation costs in connection with the re-purposing and ramp-up of the Company's Sky and Sun facilities. |
| (6) |
Out-of-period adjustments include adjustments to input assumptions related to fair value of biological assets. |
| (7) |
Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Adjusted EBITDA
Adjusted EBITDA is a Non-GAAP
Measure and can be reconciled with net income (loss), the most directly comparable GAAP financial measure, as follows:
| |
Three months ended |
| ($ thousands) |
June 30, 2024 |
March 31, 2024 |
June 30, 2023 |
| Net income (loss) from continuing operations |
4,844 |
(20,267) |
(20,197) |
| Income tax expense (recovery) |
2,857 |
(711) |
96 |
| Other income (expense) |
(6,824) |
18,719 |
5,680 |
| Share-based compensation |
3,019 |
3,029 |
2,281 |
| Depreciation and amortization |
6,494 |
6,296 |
8,241 |
| Acquisition costs |
1,001 |
2,970 |
226 |
| Inventory and biological assets fair value and impairment adjustments |
(12,348) |
(16,940) |
(3,404) |
| Business transformation related charges (1) |
4,381 |
7,539 |
5,717 |
| Out-of-period adjustments (2) |
— |
(185) |
330 |
| Non-recurring items (3) |
1,463 |
1,869 |
3,649 |
| Adjusted EBITDA (4) |
4,887 |
2,319 |
2,619 |
| (1) |
Business transformation related charges includes costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky, severance and retention costs in connection with the business transformation plan, costs associated with the retention of certain medical aggregators. Some prior period amounts have been adjusted for changes in presentation. |
| (2) |
Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods. Some prior period amounts have been adjusted for changes in presentation. |
| (3) |
Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs. |
| (4) |
Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the MD&A. Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs, and non-recurring charges related to non-core bulk cannabis wholesales to be comparable to the current period presentation. |
Adjusted SG&A
Adjusted SG&A is a Non-GAAP
Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial
measure, as follows:
| |
Three months ended |
| ($ thousands) |
June 20, 2024 |
March 31, 2024 |
June 30, 2023 |
| Sales and marketing |
14,024 |
14,530 |
12,670 |
| General and administration |
22,524 |
25,418 |
21,349 |
| Business transformation costs |
(4,868) |
(6,862) |
(4,063) |
| Out-of-period adjustments |
— |
(642) |
(330) |
| Non-recurring costs |
(284) |
(1,093) |
(593) |
| Adjusted SG&A (1) |
31,396 |
31,351 |
29,033 |
| (1) |
Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
| (2) |
Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Free Cash Flow
The table below outlines free
cash flow for the periods ended:
| |
Three months ended |
| ($ thousands) |
June 30, 2024 |
March 31, 2024(2) |
June 30, 2023(2) |
| Cash used in operating activities from continuing operations before changes in non- cash working capital |
(1,822) |
(10,074) |
(13,005) |
| Changes in non-cash working capital |
10,682 |
(10,335) |
3,814 |
| Net cash provided by (used in) operating activities from continuing operations |
8,860 |
(20,409) |
(9,191) |
| Less: maintenance capital expenditures(1) |
(2,370) |
(1,457) |
(2,495) |
| Free cash flow(1) |
6,490 |
(21,866) |
(11,686) |
| (1) |
Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth. |
| (2) |
Free cash flow is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
Working Capital
Working capital is a Non-GAAP
Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure,
as follows:
| |
Three months ended |
| ($ thousands) |
June 30, 2024 |
March 31, 2024 |
June 30, 2023 |
| Total current assets |
439,366 |
426,605 |
399,311 |
| Total current liabilities |
(116,803) |
(124,620) |
(207,110) |
| Working capital(1) |
322,563 |
301,985 |
192,201 |
| (1) |
Working capital for the three months ended March 31, 2024 and June 30, 2023 has been adjusted. Refer to discussion under "Liquidity and Capital Resources" section of the MD&A. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-fiscal-2025-first-quarter-results-and-delivers-positive-free-cash-flow-302216105.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2024/07/c7790.html
%CIK: 0001683541
For further information: For Media: Michelle Lefler, VP, Communications
& PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com
CO: Aurora Cannabis Inc.
CNW 07:00e 07-AUG-24
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Aurora Cannabis (NASDAQ:ACB)
Historical Stock Chart
From Dec 2023 to Dec 2024
